Loading...
Anaptysbio Q4 2024 Earnings Report
AnaptysBio reported its fourth quarter and full year 2024 financial results, highlighting positive Phase 2b data for rosnilimab in rheumatoid arthritis and a strong cash position.
Key Takeaways
AnaptysBio announced positive Phase 2b data for rosnilimab in rheumatoid arthritis, showing impressive safety, tolerability, and efficacy. The company reported a net loss of $21.8 million for Q4 2024, with collaboration revenue of $43.1 million. Cash and investments stood at $420.8 million at year-end 2024, with a reiterated cash runway through year-end 2027.
Rosnilimab achieved positive results from its Phase 2b rheumatoid arthritis trial, demonstrating highest-ever reported CDAI LDA response over 6 months.
Top-line Phase 2 data for rosnilimab in ulcerative colitis is now anticipated in Q4 2025, moved up from previous expectations.
AnaptysBio entered an exclusive global license agreement with Vanda Pharmaceuticals for imsidolimab, receiving $15 million upfront.
The company ended 2024 with approximately $420.8 million in cash and investments, reiterating a cash runway through year-end 2027.
Anaptysbio
Anaptysbio
Forward Guidance
AnaptysBio anticipates reporting full clinical and translational data for rosnilimab in RA in Q2 2025 and top-line Phase 2 data for rosnilimab in UC in Q4 2025. The company expects to initiate a Phase 1a trial for ANB101 in Q1 2025 and disclose the Phase 1b indication for ANB033 at a 2025 R&D event. GSK anticipates top-line data from COSTAR Lung Phase 3 trial in H1 2025 and AZUR-1 pivotal Phase 2 trial in 2026.
Positive Outlook
- Full clinical and translational data for rosnilimab in RA expected in Q2 2025.
- Top-line Phase 2 data for rosnilimab in UC moved up to Q4 2025.
- Phase 1a trial for ANB101 to initiate in Q1 2025.
- Potential for future regulatory approvals and sales milestones from Vanda Pharmaceuticals agreement.
- Potential for additional milestones and royalties from GSK collaboration.
Challenges Ahead
- No specific negative forward guidance was provided in the report.